Associate Director / Director, Distribution and GPOs

Job Description

Job Description

JOB TITLE : Associate Director / Director, Distribution and GPOs

LOCATION : Field-Based

DATE PREPARED : October 22, 2025

SUMMARY :

The Associate Director / Director of Distribution and GPOs is responsible for developing and executing strategic plans for assigned accounts to support the successful commercialization of AVEO’s lead oncology agent, FOTIVDA (tivozanib). This role will serve as the primary contact between AVEO and designated trade, distribution & GPO partners. The role will lead all account initiatives and is responsible for achieving expected business objectives across the oncology portfolio of AVEO products. Close collaboration with multiple stakeholders including sales, marketing, market access, medical affairs, HEOR, compliance / legal and finance is required to ensure successful commercialization of products within the portfolio.

JOB SUMMARY :

• Develop, define, and implement account strategies and objectives for the continued successful commercialization of FOTIVDA (tivozanib) and potential future product launches
• Ensure strong business relationships with assigned accounts
• Execute action plans to compliantly maximize access to AVEO products
• Contribute effectively to pricing and contracting strategy development
• Effectively communicate account positioning with internal stakeholders
• Continual assessment of the GPO competitive landscape and refinement of and adjust strategies and tactics to maximize FOTIVDA usage
• Optimal budget management and communication to GTN inputs
• Monitor trends and potential coverage and reimbursement issues, existing and emerging government and payer policies, competitive pricing and contracting strategies, and potential barriers to provider and patient access.

REQUIRED QUALIFICATIONS / EXPERIENCE (BASIC QUALIFICATIONS) :

About AVEO

AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has several other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.

All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.